DGIdb - CELECOXIB Drug Record

CELECOXIB chembl:CHEMBL118 Antineoplastic

Alternate Names:

DFN-15
ONSENAL
CELEBRA
CELEBREX
CELECOXIB
DFN15
SC-58635
CELECOX®
CELECOXIBUM
CELOCOXIB
4-[5-(4-METHYLPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL]BENZENE-1-SULFONAMIDE
CÉLÉCOXIB
4-[5-(4-METHYLPHENYL)-3-TRIFLUOROMETHYL)-1H-PYRAZOL-YL]BENZENESULFONAMIDE
ONSENAL®
P-(5-P-TOLYL-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL)BENZENESULFONAMIDE
drugbank:00482
pubchem.compound:2662
chemidplus:169590-42-5
rxcui:140587
chembl:CHEMBL118

Drug Info:

FDA Approval	approved
Drug Class	Small molecule
Drug Indications	NSAID
Drug Categories	therapeutic uses
Drug Categories	sulfur compounds
Drug Categories	sulfones
Drug Categories	sulfonamides
Drug Categories	sensory system agents
Drug Categories	pyrazoles
Drug Categories	physiological effects of drugs
Drug Categories	pharmacologic actions
Drug Categories	peripheral nervous system agents
Drug Categories	organic chemicals
Drug Categories	musculo-skeletal system
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	methemoglobinemia associated agents
Drug Categories	inorganic chemicals
Drug Categories	heterocyclic compounds, 1-ring
Drug Categories	heterocyclic compounds
Drug Categories	enzyme inhibitors
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp2d6 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp2d6 inhibitors
Drug Categories	cytochrome p-450 cyp2c9 substrates
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors
Drug Categories	cyclooxygenase inhibitors
Drug Categories	cyclooxygenase 2 inhibitors
Drug Categories	chemical actions and uses
Drug Categories	central nervous system agents
Drug Categories	azoles
Drug Categories	antirheumatic agents
Drug Categories	antiinflammatory and antirheumatic products, non-steroids
Drug Categories	antiinflammatory and antirheumatic products
Drug Categories	anti-inflammatory agents, non-steroidal
Drug Categories	anti-inflammatory agents
Drug Categories	analgesics, non-narcotic
Drug Categories	analgesics
Drug Categories	amides
Drug Groups	investigational
Drug Groups	approved
Drug Type	small molecule
Drug Categories	selective cyclooxygenase 2 inhibitors (nsaids)
Drug Categories	photosensitizing agents
Drug Categories	p-glycoprotein substrates
Drug Categories	nephrotoxic agents
Drug Categories	gynecological antiinfectives and antiseptics
Drug Categories	genito urinary system and sex hormones
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	cytochrome p-450 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp2d6 substrates
Drug Categories	cytochrome p-450 cyp2d6 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 substrates
Drug Categories	cyclooxygenase-2 (cox-2) inhibitors
Drug Categories	cox-2 inhibitors
Drug Categories	bsep/abcb11 inhibitors
Drug Categories	bcrp/abcg2 substrates
Drug Categories	antineoplastic and immunomodulating agents
Drug Categories	agents that produce hypertension
Drug Categories	agents causing hyperkalemia

(9 More Sources)

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics
Zhu et al., 2004, From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors., Cancer Res.
Kulp et al., 2004, 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells., Cancer Res.
Li et al., 2006, A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth., J. Gastrointest. Surg.
Tseng et al., 2006, Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor., Mol. Pharmacol.
Tong et al., 2005, Neutrophil gelatinase-associated lipocalin as a survival factor., Biochem. J.
Arico et al., 2002, Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line., J. Biol. Chem.
Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
Li H et al., 2011, Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)., J Med Chem
Lu et al., 2002, Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids., Cancer Lett.
Sigthorsson et al., 2002, COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice., Gastroenterology
Scheiman, 2002, Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors., Cleve Clin J Med
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Reddy et al., 2002, Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors., J. Environ. Pathol. Toxicol. Oncol.
Ahmad et al., 2002, Renal failure associated with the use of celecoxib and rofecoxib., Drug Saf
Grosser T, 2009, Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy., J Investig Med
Namba et al., 2007, Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells., Mol. Pharmacol.
Kim et al., 2007, GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells., Carcinogenesis
Kim et al., 2006, GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells., Carcinogenesis
Tsutsumi et al., 2004, Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis., Cell Death Differ.
Fabricio et al., 2005, The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats., Am. J. Physiol. Regul. Integr. Comp. Physiol.
Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.
Kim SH et al., 2017, Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite., Arch Pharm Res
Liu R et al., 2015, Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects., Eur J Pharm Sci
Gupta A et al., 2015, Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy., Pain Med
Prieto-Pérez R et al., 2013, Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib., J Clin Pharmacol
Pilotto A et al., 2007, Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms., Gastroenterology
Fries S et al., 2006, Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2., Gastroenterology
Stempak D et al., 2005, Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient., Clin Pharmacol Ther
Kirchheiner J et al., 2003, Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites., Pharmacogenetics
Tang C et al., 2001, In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics., Pharmacogenetics
Koeberle A et al., 2009, Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1., Bioorg Med Chem
Hanke T et al., 2013, Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1., Bioorg Med Chem
Koeberle A et al., 2008, Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase., J Med Chem
Sibilia et al., 2008, Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk., Br. J. Pharmacol.
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Ma et al., 2002, Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance., Proc. Natl. Acad. Sci. U.S.A.
McKew JC et al., 2008, Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib., J Med Chem
Vardar-Sengül et al., 2006, Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats., J. Periodontol.
Narayanan et al., 2006, Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells., Int. J. Cancer
Haupt et al., 2006, Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species., Anticancer Drugs
Andrews et al., 2005, Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells., Breast Cancer Res. Treat.
Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
Weber A et al., 2004, Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition., J Med Chem
Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem
Assefnia S et al., 2014, Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies., Oncotarget

CELECOXIB CA12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB PTGS1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

CELECOXIB PDPK1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Zhu et al., 2004, From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors., Cancer Res.

Kulp et al., 2004, 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells., Cancer Res.

Li et al., 2006, A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth., J. Gastrointest. Surg.

CELECOXIB PTGS2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name celecoxib,Celebrex, Celecox

Publications:

Lu et al., 2002, Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids., Cancer Lett.

Sigthorsson et al., 2002, COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice., Gastroenterology

Scheiman, 2002, Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors., Cleve Clin J Med

CELECOXIB CA2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Weber A et al., 2004, Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition., J Med Chem

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

CELECOXIB CDH11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Assefnia S et al., 2014, Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies., Oncotarget
CELECOXIB CA3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem
CELECOXIB APC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Preclinical

Publications:

Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.
CELECOXIB PIK3CA

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Pdx

Response Type sensitive

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
CELECOXIB ALOX12

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics
CELECOXIB CASP3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB ATP2A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

CELECOXIB STAT3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Li H et al., 2011, Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)., J Med Chem

CELECOXIB CACNA2D1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB MMP9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB ATP2A3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA1D

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA1G

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CDKN1A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB IL23R

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics
CELECOXIB CA9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CYP3A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA2D3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB BCAR1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB KCNQ4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB PDK1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA2D4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

CELECOXIB DDIT3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Namba et al., 2007, Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells., Mol. Pharmacol.

Kim et al., 2007, GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells., Carcinogenesis

Kim et al., 2006, GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells., Carcinogenesis

CELECOXIB ATP2A2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CTNNB1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA1B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNB2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB PPARG

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB IGFBP3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB EDN1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Fabricio et al., 2005, The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats., Am. J. Physiol. Regul. Integr. Comp. Physiol.

CELECOXIB CYP2C9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kim SH et al., 2017, Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of celecoxib and its carboxylic acid metabolite., Arch Pharm Res

Liu R et al., 2015, Influence of genetic polymorphisms on the pharmacokinetics of celecoxib and its two main metabolites in healthy Chinese subjects., Eur J Pharm Sci

Gupta A et al., 2015, Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy., Pain Med

CELECOXIB CASP9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

CELECOXIB PTGES

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics

Koeberle A et al., 2009, Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1., Bioorg Med Chem

Hanke T et al., 2013, Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1., Bioorg Med Chem

CELECOXIB KCNQ2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA1F

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB GHRL

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sibilia et al., 2008, Central ghrelin gastroprotection involves nitric oxide/prostaglandin cross-talk., Br. J. Pharmacol.
CELECOXIB CACNA1C

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA1I

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNB3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CYP3A5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
CELECOXIB KCNQ1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CDKN1B

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB VEGFA

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB COL18A1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ma et al., 2002, Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance., Proc. Natl. Acad. Sci. U.S.A.

CELECOXIB MT-CO2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

McKew JC et al., 2008, Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib., J Med Chem

CELECOXIB CACNA1S

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA2D2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB KCNQ5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

CELECOXIB BGLAP

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Vardar-Sengül et al., 2006, Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats., J. Periodontol.

CELECOXIB KCNQ3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB HSPA4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Narayanan et al., 2006, Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells., Int. J. Cancer
CELECOXIB ABL1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Haupt et al., 2006, Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species., Anticancer Drugs
CELECOXIB PTGER4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics
CELECOXIB CACNA1E

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB PLAU

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Andrews et al., 2005, Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells., Breast Cancer Res. Treat.
CELECOXIB CACNA1H

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNB4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB CACNA1A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics
CELECOXIB AR

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
CELECOXIB RORC

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
CELECOXIB NFE2L2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00482

Version: 5.1.7

Alternate Names:

CELECOXIB DrugBank Drug Name

169590-42-5 CAS Number

Accel-celecoxib Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Zhu et al., 2004, From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors., Cancer Res.

Tseng et al., 2006, Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor., Mol. Pharmacol.

Li et al., 2006, A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth., J. Gastrointest. Surg.

TdgClinicalTrial: CELECOXIB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications NSAID

Drug Class Small molecule

FDA Approval approved

Publications:

NCI: CELECOXIB

Version: 14-September-2017

Alternate Names:

C1728 NCI drug code

Drug Info:

Publications:

Fabricio et al., 2005, The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats., Am. J. Physiol. Regul. Integr. Comp. Physiol.

Haupt et al., 2006, Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species., Anticancer Drugs

Tsutsumi et al., 2004, Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis., Cell Death Differ.

DTC: CELECOXIB

Version: 02-September-2020

Alternate Names:

CHEMBL118 ChEMBL Drug ID

Drug Info:

Publications:

McKew JC et al., 2008, Indole cytosolic phospholipase A2 alpha inhibitors: discovery and in vitro and in vivo characterization of 4-{3-[5-chloro-2-(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic acid, efipladib., J Med Chem

Li H et al., 2011, Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)., J Med Chem

Koeberle A et al., 2008, Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase., J Med Chem

PharmGKB: celecoxib

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Tang C et al., 2001, In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics., Pharmacogenetics

JAX-CKB: Celecoxib

Version: 15-September-2020

Alternate Names:

Drug Info:

Publications:

Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

TALC: CELECOXIB
- Version: 12-May-2016
Alternate Names:

CELECOXIB Primary Drug Name

CELECOXIB Drug Generic Name

CELEBREX Drug Trade Name

Drug Info:

Publications:
TTD: Celecoxib
- Version: 2020.06.01
Alternate Names:

D03RTS TTD Drug ID

Drug Info:

Publications:
GuideToPharmacologyInteractions: 178100241
- Version: 20-July-2020
Alternate Names:

CELECOXIB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL118
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
MyCancerGenomeClinicalTrial: CELECOXIB
- Version: 30-February-2014
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL118
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Celecoxib
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	False

Notes
Novel drug target	Established target
Trial Name	celecoxib,Celebrex, Celecox

Indication/Tumor Type	colorectal cancer
Response Type	sensitive
Approval Status	Preclinical

Evidence Type	Actionable
Approval Status	Preclinical - Pdx
Response Type	sensitive

CELECOXIB	DrugBank Drug Name
169590-42-5	CAS Number
Accel-celecoxib	Drug Brand

CELECOXIB	Primary Drug Name
CELECOXIB	Drug Generic Name
CELEBREX	Drug Trade Name

CELECOXIB Drug Record

CELECOXIB chembl:CHEMBL118 Antineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? False

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Novel drug target Established target Trial Name celecoxib,Celebrex, Celecox

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Assefnia S et al., 2014, Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies., Oncotarget

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type sensitive Approval Status Preclinical

Publications: Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Pdx Response Type sensitive

Publications: Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for &lt;i&gt;PIK3CA&lt;/i&gt;-altered head and neck cancer., J Exp Med

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Li H et al., 2011, Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)., J Med Chem

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Novel drug target Established target

Trial Name celecoxib,Celebrex, Celecox

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Assefnia S et al., 2014, Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies., Oncotarget

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Nishimori I et al., 2007, Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides., Bioorg Med Chem

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type sensitive

Approval Status Preclinical

Publications:

Buchanan et al., 2007, Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer., Cancer Res.

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Pdx

Response Type sensitive

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

Interaction Types & Directionality:

n/a

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Li H et al., 2011, Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)., J Med Chem

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Kraus S et al., 2013, Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Gong L et al., 2012, Celecoxib pathways: pharmacokinetics and pharmacodynamics., Pharmacogenet Genomics

Interaction Types & Directionality:

n/a

Publications:

Fabricio et al., 2005, The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats., Am. J. Physiol. Regul. Integr. Comp. Physiol.